# Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

> **NCT00193245** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 80 (—)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00193245
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2005-10
- **Final completion:** 2009-01
- **Target enrollment:** 80 (—)
- **Last updated:** 2010-06-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193245, "Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00193245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*